In last trading session, Rapport Therapeutics Inc (NASDAQ:RAPP) saw 0.49 million shares changing hands with its beta currently measuring 0.24. Company’s recent per share price level of $11.43 trading at -$0.38 or -3.22% at ring of the bell on the day assigns it a market valuation of $417.17M. That closing price of RAPP’s stock is at a discount of -160.19% from its 52-week high price of $29.74 and is indicating a premium of 43.74% from its 52-week low price of $6.43. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.12 million shares which gives us an average trading volume of 175.56K if we extend that period to 3-months.
For Rapport Therapeutics Inc (RAPP), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Rapport Therapeutics Inc (NASDAQ:RAPP) trade information
Upright in the red during last session for losing -3.22%, in the last five days RAPP remained trading in the green while hitting it’s week-highest on Tuesday, 06/24/25 when the stock touched $11.43 price level, adding 8.71% to its value on the day. Rapport Therapeutics Inc’s shares saw a change of -49.65% in year-to-date performance and have moved 4.67% in past 5-day. Rapport Therapeutics Inc (NASDAQ:RAPP) showed a performance of 20.19% in past 30-days. Number of shares sold short was 2.83 million shares which calculate 12.77 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 35 to the stock, which implies a rise of 67.34% to its current value. Analysts have been projecting 35 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -206.21% in reaching the projected high whereas dropping to the targeted low would mean a loss of -206.21% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 13.10% while estimates for its earnings growth in next 5 years are of -8.86%.
Rapport Therapeutics Inc (NASDAQ:RAPP)’s Major holders
Insiders are in possession of 6.40% of company’s total shares while institution are holding 105.23 percent of that, with stock having share float percentage of 112.43%. Investors also watch the number of corporate investors in a company very closely, which is 105.23% institutions for Rapport Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at RAPP for having 4.98 million shares of worth $115.91 million. And as of 2024-06-30, it was holding 13.6245 of the company’s outstanding shares.
The second largest institutional holder is ARCH VENTURE MANAGEMENT, LLC, which was holding about 3.73 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.1944 of outstanding shares, having a total worth of $86.73 million.
On the other hand, SMALLCAP WORLD FUND INC and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 2.6 shares of worth $29.75 million or 7.13% of the total outstanding shares. The later fund manager was in possession of 1.54 shares on Apr 30, 2025 , making its stake of worth around $17.64 million in the company or a holder of 4.23% of company’s stock.
